Department of Pharmaceutics
Syllbus
NO. | OBJECTIVE | No. of attribute covered |
---|---|---|
1 | Study the chemistry of natural products, namely glycosides, flavonoids, volatile oils, fixed oils, and tannins. | 1-10 |
2 | Study the phytochemistry and pharmacology of secondary medicinal plant constituents. | 1-9 |
3 | Study the uses of these constituents and the plants containing these constituents. | 1-10 |
4 | Understand nature and role of hormones and vitamins | 10 |
5 | Study the chemistry and pharmacology of toxic non- medicinal plants | 11 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Dilution and concentration of pharmaceutical preparations. | 10 |
2 | Isotonic solutions. | 6 |
3 | Electrolyte solutions (milliequivalents, millimoles and milliosmoles). | 6 |
4 | Constituted solutions, I.V admixtures and flow rate calculations. | 8 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Demonstration of different glass wares and equipments used in the field of pharmacy. | 2 |
2 | Pharmaceutical measurements. | 4 |
3 | Volume measurements. | 4 |
4 | Preparation of aromatic waters. | 2 |
5 | Preparation of simple solutions. | 4 |
6 | Reducing and enlarging prescription contents. | 4 |
7 | Percentages in calculating prescription contents. | 4 |
8 | Stock solutions and dilution technique during dispensing technique. | 6 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | States of matter, binding forces between molecules, gases,liquids, solid and crystalline matters; phase equilibria and phase rule; thermal analysis. | 10 |
2 | Thermodynamics, first law, thermochemistry, second law,third law, free energy function and applications. | 8 |
3 | Solutions of non-electrolytes, properties, ideal and real colligative properties, molecular weight determination. | 7 |
4 | Solution of electrolytes, properties, Arrhenius theory of dissociation, theory of strong electrolytes, ionic strength, Debye-Huchle theory, coefficients for expressing colligative properties. | 5 |
5 | Ionic equilibria, modern theories of acids, bases and salts, acid-baseequilibria, calculation of pH, acidity constants, the effect of ionic strength and free energy. | 8 |
6 | Buffered and isotonic solutions: Buffer equation; buffer capacity; methods of adjusting tonicity and pH; buffer and biological system. | 7 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Expression of concentrations in pharmaceutical preparations | 4 |
2 | Two component systems containing liquid phases. | 4 |
3 | Three component systems. | 4 |
4 | Tie linear for three component systems. | 4 |
5 | Partition coefficient: Measurements and evaluation. | 2 |
6 | Solubility methods. | 4 |
7 | Buffer solutions. | 4 |
8 | Determination of solubility product constant of slightly soluble salts. | 4 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Solubility and distribution phenomena, solvent-solute interactions, solubility of gases in liquids, solubility of liquids in liquids, solubility of non-ionic solids in liquids, distribution of solutes between immiscible solvents. | 10 |
2 | Complexation, classification of complexes, methods of analysis, thermodynamic treatment of stability constants. | 5 |
3 | Kinetics, rate and orders of reactions, influence of temperature and other factors on reactions rate, decomposition of medicinal agents and accelerated stability analysis. | 9 |
4 | Interfacial phenomena, liquid interfaces, surface free energy, measurement of interfacial tension, spreading coefficient, surface active agents and wetting phenomena. | 5 |
5 | Colloids, dispersed system and its pharmaceutical application, types of colloidal systems, kinetic properties, diffusion, zeta potential, solubilization. | 5 |
6 | Micrometrics, particle size, methods of determining particle size, particle shape and surface area, porosity, density. | 3 |
7 | Rheology, Newtonian systems, thixotropy measurement, negative thixotropy, determination of thixotropy. | 5 |
8 | Polymer science, definitions pharmaceutical applications, molecular weight averages | 3 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Solubilization of components of pharmaceutical preparations. | 4 |
2 | Solubilization of Aspirin. | 4 |
3 | Review and tutorial | 2 |
4 | Surface tension: measurements and calculations. | 4 |
5 | Rate kinetic: Application in stability of pharmaceutical stability. | 4 |
6 | Review and tutorial | 2 |
7 | Viscosity: Measurements and calculation. | 6 |
8 | Adsorption isotherm. | 4 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Dispersed systems: their classification; comparisons between different systems. | 2 |
2 | Solutions and types of solutions. | 2 |
3 | Solubility: Factors affecting solubility; expression of dissolution; dissolution rate versus solubility; preparation of solutions containing non-volatile materials. | 4 |
4 | Official solutions; classification of official solutions; preparation and uses. | 4 |
5 | Aqueous solutions containing aromatic principles; aromatic waters; methods of preparations; stability. | 4 |
6 | Syrups: sugar based syrups; artificial and sorbitol based syrups; stability of syrups. | 4 |
7 | Definition and methods of clarification; filter aids in clarification. | 3 |
8 | Preparation of solutions using mixed solvent systems; spirits, and elixirs. | 3 |
9 | Extraction; maceration and percolation. | 3 |
10 | Tinctures; fluid extracts; extracts of resins and oleoresins. | 4 |
11 | Colloidal dispersions; lyophilic; lyophobic. | 6 |
12 | Coarse dispersion; suspensions. | 6 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Solutions (Into body cavity, oral and external use). | 4 |
2 | Syrups: Preparation techniques and quality evaluation. | 4 |
3 | Review and tutorial | 2 |
4 | Elixirs: Preparation techniques and quality evaluation. | 4 |
5 | Spirits: Preparation techniques and quality evaluation. | 4 |
6 | Review and tutorial | 2 |
7 | Suspensions: Preparation techniques and quality evaluation. | 6 |
8 | Dispersion of oils in inhalations. | 4 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Emulsions; purpose of emulsification; methods of emulsification; emulsifying agents; HLB system; stability of emulsions. | 10 |
2 | Lotions; liniments and collodions. | 5 |
3 | Suppositories. | 6 |
4 | Powdered dosage forms. | 10 |
5 | Semisolid dosage forms. | 10 |
6 | Incompatibilities in pharmaceutical dosage forms. | 4 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Emulsions: Preparation techniques and quality evaluation. | 4 |
2 | Suppositories: Preparation techniques and quality evaluation. | 4 |
3 | Review and tutorial | 2 |
4 | Powders: Preparation techniques and quality evaluation. | 4 |
5 | Capsules: Preparation techniques and quality evaluation. | 4 |
6 | Review and tutorial | 2 |
7 | Semisolid dosage forms: Preparation techniques and quality evaluation. | 8 |
8 | Review and tutorial | 2 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Introduction to biopharmaceutics. | 2 |
2 | Biopharmaceutic aspects of products; drug absorption; mechanisms of absorption; physicochemical factors; dissolution rate; effects of excipients; type of dosage forms. | 6 |
3 | One compartment open model. | 2 |
4 | Multicompartment models. | 2 |
5 | Pharmacokinetics of drug absorption. | 2 |
6 | Bioavailability and bioequivalence. | 2 |
7 | Clearance of drugs from the biological systems. | 2 |
8 | Hepatic elimination of drugs. | 2 |
9 | Protein binding of drugs. | 2 |
10 | Intravenous infusion | 2 |
11 | Multiple dosage regimens. | 2 |
12 | Non-linear pharmacokinetics. | 2 |
13 | Dosage adjustment in renal diseases. | 2 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Preparation of calibration curve of salicylic acid. | 2 |
2 | In vitro evaluation of bulk laxative. | 2 |
3 | In vitro evaluation of antacids. | 2 |
4 | Dissolution of tablets. | 4 |
5 | Review and tutorial | 2 |
6 | Determination of pharmacokinetic parameters from CP-time by residual method. | 4 |
7 | Determination of pharmacokinetic parameters from CP-time by trapezoidal method. | 4 |
8 | Determination of pharmacokinetic parameters from urine excretion samples. | 4 |
9 | Hydrolysis of aspirin in buffer pH 6.8. | 4 |
10 | Review and tutorial | 2 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | The principles of pharmaceutical processing; mixing; fluid mixing; flow characteristics; mechanisms of mixing; mixing equipments; batch and continuous mixing; mixer selection; solid mixing theory and particulate solid variables; forces and mechanisms. | 7 |
2 | Milling; pharmaceutical application; size measurement methods; theory and energy of commenution; types of mills; factors influencing milling; selection of mill techniques; specialized drying methods. | 7 |
3 | Drying: definition; purpose; humidity measurement; theory of drying; drying of solids, and classification of dryer; specialized drying methods. | 7 |
4 | Clarification and filtration: Theory; filter media; filter aids; selection of drying method; non-sterile and sterile operations; integrity testing; equipments and systems (commercial and laboratory). | 7 |
5 | Sterilization; validation of methods; microbial death kinetics; methods of sterilization (thermal and non-thermal); mechanisms; evaluation. | 7 |
6 | Pharmaceutical dosage form design; pre-formulation; preliminary evaluation; bulk characterization; solubility and stability analysis. | 3 |
7 | Pharmaceutical dosage forms; sterile products; development; formulation; production; processing; quality control. | 7 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Introduction in industrial pharmacy and pre-formulation. | 2 |
2 | Effervescent granules: Preparation and characterization. | 2 |
3 | Flow properties and rheology of granules. | 4 |
4 | Tablet dosage form: Preparation and characterization. | 4 |
5 | Review and tutorial | 2 |
6 | Evaluation of tablets. | 4 |
7 | Preparation of children aspirin by wet granulation method. | 2 |
8 | Sustained release dosage forms: Preparation and characterization. | 4 |
9 | Coating techniques of tablets. | 4 |
10 | Review and tutorial | 2 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Pharmaceutical dosage forms: Tablets; role in therapy; advantages and disadvantages; formulation; properties; evaluation; machines used in tableting; quality control; problems; granulation, and methods of production; excipients, and types of tablets. | 10 |
2 | Tablet coating; principles; properties; equipments; processing; types of coating (sugar and film); quality control, and problems. | 4 |
3 | Capsules: Hard gelatin capsules; materials; production; filling equipments; formulation; special techniques. | 3 |
4 | Soft gelatin capsules: Manufacturing methods; nature of capsule shell and content; processing and control; stability. | 2 |
5 | Micro-encapsulation; core and coating materials; stability; equipments and methodology. | 2 |
6 | Modified (sustained release) dosage forms; theory and concepts; evaluation and testing; formulation. | 3 |
7 | Liquids: Formulation; stability and equipments. | 3 |
8 | Suspensions: Theory; formulation and evaluation. | 3 |
9 | Emulsions: Theory and application; types; formulation; equipments and quality control. | 3 |
10 | Semisolids: Percutaneouse absorption; formulation; types of bases (vehicles) | 3 |
11 | Suppositories: Rectal absorption; uses of suppositories; types of bases; manufacturing processes; problems and evaluation. | 3 |
12 | Pharmaceutical aerosols: Propellants; containers; formulation; types and selection of components; stability; manufacturing; quality control and testing. | 6 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Direct compression method for preparation of tablets. | 4 |
2 | Wet granulation method for preparation of tablets. | 4 |
3 | Dry granulation method for preparation of tablets. | 4 |
4 | Review and tutorial | 2 |
5 | Evaluation of tablets. | 4 |
6 | Capsules dosage form: Preparation and evaluation. | 6 |
7 | Parenteral dosage forms | 4 |
8 | Review and tutorial | 2 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Pharmaceutical consideration: The need for the dosage form. | 1 |
2 | General consideration of the dosage form. | 3 |
3 | Pre-formulation; physical description, microscopic examination. | 2 |
4 | Melting point; phase rule; particle size; polymorphism; solubility. | 2 |
5 | Permeability; pH; partition coefficient; pka; stability; kinetics; shelf life. | 2 |
6 | Rate reaction; enhancing stability. | 2 |
7 | Formulation consideration: Excipients; definition and types; appearance; palatability; flavoring. | 2 |
8 | Sweetening; coloring pharmaceuticals; preservatives; sterilization; preservatives selection. | 2 |
9 | Biopharmaceutical considerations: Principle of drug absorption; dissolution of the drugs. | 4 |
10 | Bioavailability and bioequivalancy; FDA requirements. | 3 |
11 | Assessment of bioavailability; bioequivalence among drug products. | 3 |
12 | Pharmacokinetic principles: Half life; clearance; dosage regimen considerations. | 4 |
NO. | SUBJECTS | HOURES |
---|---|---|
1 | Biotechnology - introduction | 1 |
2 | Formulation of biotechnology product (biopharmaceutical consideration) Microbial consideration- sterility-pyrogen viral decontamination . Excipients of parental products - solubility enhancer-anti adsorption agents buffer components preservatives – osmotic agents. | 4 |
3 | Route of administration : Parentral route , Oral route Alternative | 5 |
4 | Pharmacokinetic of peptides and proteins: Introduction, Elimination of proteins (proteolysis-excretion-metabolism). | 5 |
Staff Member
vission
The vision of Pharmaceutics department is to be focusing on innovative work in research and education that related to pharmaceutics and drug delivery to achieve the superiority in this respect.
Mission
The mission of Pharmaceutics department involved two targets, one related to education and training mission and other related to research and innovation mission. The first target attained by offering undergraduate and postgraduate students with essential knowledge for understanding the physicochemical and biopharmaceutical aspects of dosage form design, evaluation and manufacturing. Whereas the second target accomplished by performing and directing new knowledge to external partners to amend drug delivery and patients care.
SIENTFIC ACTIVITY DEPARTMENT
×
Name : Assist.Prof.Dr. Feryal Hashim Rada
Assistant Professor / Central Scientific Promotion Committee / Al- Nahrain University.
1. Certificate of e-learning skill 2020-2021
Member of middle east molecular biology sources society (MEMBS ) .A007435 on 25/12/2017
1. Four books of Acknowledgments from the minister of higher education and scientific research ( 208 on 6/5/2020),(532 on 11/8/2020),(432 on 1/3/2021), (1429 on 26/8/2021).
Therapeutics and Clinical Biochemistry that involve:
1. Rada FH. Platelets prohibition with clopidogrel alone versus with proton-pump inhibitors. Biomed Biotechnol Res J 2021;5:327-30.
CV Of DR.Fryal Hashim

PERSONAL Information
Name : Assist.Prof.Dr. Feryal Hashim Rada
Gender: Female
Nationality: Iraq
E-mail: fermsc33@yahoo.com
Residential Address: Baghdad / Iraq
Education Qualifications
Assistant Professor / Central Scientific Promotion Committee / Al- Nahrain University.
Ph.D.: Doctorate of Philosophy degree in Clinical Biochemistry / Precise specialization is Therapeutic and Clinical Biochemistry / from
College of Medicine /Al-Nahrain University.
M.Sc.: Master of Science degree in Clinical Biochemistry / Precise specialization is Endocrinology / from College of Medicine /Al-Mustansiriya University .
B.Sc.: Bachelor of
Science degree in Pharmacy from College of Pharmacy / Baghdad University.
Skills
1. Certificate of e-learning skill 2020-2021
2. Certificate of Peer Reviewer from Publone Academia. 2019.
3. Certificate of examining and assessing the researches of the Inventing requests of Central Organization for Standardization
and Quality Control (COSQC)/ Iraq.
4. Certificate of participation and assessment as (Auditor) in a training program of laboratories accreditation ISO (17025) in (Quality Assurance Department /Al-Nahrain University).
5. Certificate of TOEFL Institutional Testing Program (ITP), 2010 / 2011.
6. Certificate of Internet and Computing Core Certification (IC3), 2010.
7. Certificate of training program of Computer aptitude
Professional Body Fellowship and Membership
Member of middle east molecular biology sources society (MEMBS ) .A007435 on 25/12/2017
Member of Iraqi Inventors and Innovators Society.000141 on 1/1/2018
Member of quality council in the pharmacy college (355 on 7/3/2017)
till 23/11/2017.
Member of examination committee /college of pharmacy (45 on 8/1/2017),(2016-2017).
Manager of Laboratory accreditation unit /college of pharmacy (543 on 2/9/2015) –till 23/11/2017.
Member of examination
committee /college of pharmacy /Al-Mustansiriya University (2010-2011).
Acknowledgments and Appreciation
1. Four books of Acknowledgments from the minister of higher education and scientific research ( 208 on 6/5/2020),(532 on 11/8/2020),(432 on 1/3/2021), (1429 on 26/8/2021).
2. Twelve books of Acknowledgments from the President
of Al-Nahrain University : (6/13463 on 10/10/2017), (1/146 on 3/1/2017), (6/1526 on 30/1/2017),(6/6924 on 18/5/2017), (84 on 27 / 6/ 2019),(6/12621 on 23/9/2018),(6/2076 on 12 /2/2019),(6/2075 on 12/2/2019), (6/2902 on 4/3/2019),
(99s on 20/9/2020),(9292 on 9/11/2020),(16s on 3/3/2021).
3. Two book of Acknowledgments from Vice President for scientific Affairs of Al-Nahrain University : (1/4590 on 4/4/2018),(1/12724 on 25/ 9/ 2018)
4. Five books
of Thanks and Appreciation from President of Central Organization for Standardization and Quality Control (COSQC) ,(776 on 7/3/2018),(1593 on 28/5/2018) , (2145 on 2 /8/2018),(2745 on 23 /10 /2018), (7100 on 18/3/ 2019).
5.
I bestowed five books of Thanks and Appreciation from the Dean of Pharmacy College / Al-Nahrain University: (192 on 29/1/2017), (204 on 24/2/2016), (840 on 3/7 /2016), (942 on 10/6/ 2019),(955 on 5/11/2020).
6. I bestowed four
books of Thanks and Appreciation from the President of Al-Mustansiriya University :(15333 on 19/5/2011) ,(27701 on 30/10/2011) , (31041 on 7/12/ 2011) ,(11308 on 17/4/2014).
7. I bestowed eight books of Thanks and Appreciation
from the Ministry of Health / hospitals and health centers: (C.V. 1225 on 7/6/2010).
Research Interest (Field)
Therapeutics and Clinical Biochemistry that involve:
(i) Seeking for adverse events and adverse effects of newly marketing drugs.
(ii) Seeking for new biochemical markers and assess their role in diagnosis and /or prognosis
of the diseases.
Journals Publications
1. Rada FH. Platelets prohibition with clopidogrel alone versus with proton-pump inhibitors. Biomed Biotechnol Res J 2021;5:327-30.
2. Rada FH.Impact of Osteoprotegerin and RANKL on Non-ST-segment Elevation Myocardial Infarction.IntJ
NutrPharmacolNeurolDis2021;11:206-10.
3. Rada FH.Clinical assessment of Saxagliptin therapy in diabetic patients with corpulence.Ann Rom Soc cell Biol 2021;25(5):4039- 4047
4. Rada FH. Effect of Angiotensin II Receptor Blocker Treatment on Adipokine of Corpulence
. Biomed & Pharmacol J 2020; 13(2) : 957-963.
5. Rada FH. Platelet reactivity with a third generation thienopyridine drug versus with a second-generation thienopyridine drug. Int J Res Pharm Sci.2020;11(3): 3704-3709.
6. Rada FH. Adequacy of Olmesartan monotherapy versus cotherapy in patients with essential hypertension. Int J Res Pharm Sci 2020; 11(2):1649-1654.
7. Rada Feryal H. Antiplatelet Adequacy of Cytopentyl Triazolopyrimidine versus
Clopidogrel in Patients with Coronary Heart Disease. Asian J Pharm Clin Res. 2018;11(12): 536-539. (SCOPUS,ELSEVIER)
8. Rada Feryal H. Platelet Reactivity with a Third Generation Thienopyridine Drug versus With a Second-Generation
Thienopyridine Drug. Baghdad College of Medicine, 17th Scientific Conference, 28-29 November 2018.Abstract Book page no. 50.
9. Rada Feryal H. Genetic Analysis. Eur j pharm med res . 2018; 5(10): 95-98. (Review Article)
10. Rada Feryal H. Peroxisome Proliferator- Activated Receptors Family Overview. Eur j pharm med res. 2019; 6(1):167-170 (Review Article)
11. Rada Feryal H. Oxidative stress and some inflammatory biomarkers in patients with
coronary heart disease. European journal of pharmaceutical and medical research.2018,5(1):9-12.
12. Rada Feryal H. Oxidative stress assessment in patients with diabetic nephropathy .European journal of pharmaceutical and medical
research. 2018,5(1):44-47.
13. Rada Feryal H. Assessment of pyrazino-pyrimidine compound and some inflammatory biomarkers in patients with type 2 diabetes. International Journal of Pharmaceutical Sciences and Research 2017
; 8 (6) : 2691-2695. [Emerging Sources Citation Index-Thomson Reuters].
14. Rada Feryal H. Association of lipid fractions levels with cardiovascular disease. Asian J Pharm Clin Res (innovare) 2017;10(3): 180-182. (SCOPUS,ELSEVIER)
15. Rada Feryal H. Efficacy of octreotide acetate on acromegalic patients. Euro J Pharm Med Res 2016;3(12): 31-33.
16. Rada Feryal H. Clopidogrel and liver injury in diabetic patients. Euro J Pharm Med Res 2016; 3(6):168-170.
17. Rada Feryal H. Fenofibrate adverse effects versus atorvastatin . International journal of research in pharmacy and chemistry 2016; 6 (1): 32-37.
18. Rada Feryal H. Fetuin-A in patients with kidney disease. World Journal
of Pharmaceutical Research 2016; 5(1): 240-247.
19. Rada Feryal H.Cystatin C in diabetic patients. International journal of research in pharmacy and chemistry 2015; 5(2): 274-278.
20. Rada Feryal H, Najat A Hasan ,and Mohammed
H Al Baghdadi . Hepatotoxicity of Combined Therapy of Atorvastatin with Platelet P2Y12-ADP Receptor Antagonist in Coronary Heart Disease Treated Patients. The Iraqi postgraduate medical journal 2015 ;14(1):108 – 113.
21. Hasan
Najat A , Mohammed H Al Baghdadi and Feryal H Rada. Assessment of adverse effect of atorvastatin with platelet P2Y12-ADP receptor antagonist on platelets aggregation and renal function in coronary heart disease treated patients.
International journal of research in pharmacy and chemistry 2014; 4(2): 274-282.
22. Rada Feryal H,Nahla Al-Sakkal and Abdul-Karim Yahia. Leptin in Goitrous patients. Mustansiriya medical journal 2009 ; 8(1):33-35.
×
CV Of DR. Rwaa Mohammed

PERSONAL Information